Gri bio announces abstract selected for poster discussion session at the 2025 american thoracic society (ats) international conference

La jolla, ca, april 16, 2025 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (“nkt”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been selected for poster presentation in a poster discussion session at the 2025 ats international conference being held may 18-21, 2025 in san francisco, ca. details of the presentation are as follows: title: inactivation of inkt cells after the inflammatory phase leads to significant inhibition of fibroblast activation and fibrosis in a model of pulmonary fibrosis poster board number: 810 presenter: marc hertz, phd, chief executive officer of gri bio session: d21 - immunological insights in lung inflammation and repair date and time: wednesday, may 21, 2025 from 8:15-10:15 am pt location: room 2022/2024 (west building, level 2), moscone center for more information about the 2025 ats international conference, please visit the conference website, here.
GRI Ratings Summary
GRI Quant Ranking